Loading
A phase 1/2 trial of PM8002 in non-small-cell lung cancer and small-cell lung cancer, run by BioNTech SE, now recruiting.
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 1/2 interventional study registered as NCT07111520 by BioNTech SE, with 880 participants planned, started 2025-09-22 and due to reach its primary completion in 2028-11. Interventions recorded: BNT326, Pumitamig. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, BioNTech, Small-cell lung cancer.
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/